Illumina, Inc. with ticker code (ILMN) now have 17 confirmed analysts covering the stock with the consensus suggesting a rating of ‘hold’. The range between the high target price and low target price is between 318 and 125 calculating the average target price we see $213.82. Now with the previous closing price of $142.41 this would indicate that there is a potential upside of 50.1%. The 50 day MA is $173.13 and the 200 day moving average is $198.98. The company has a market cap of 22.25B. The stock price for the company is currently is currently 140.53 USD
The potential market cap would be $33,400,870,456 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of 28.32 and a -0.79% return on assets.
Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.
